- Home
- YSG vs EDIT Comparison
YSG vs EDIT Comparison
Compare YSG & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSG
- EDIT
- Stock Information
- Founded
- YSG 2016
- EDIT 2013
- Country
- YSG China
- EDIT United States
- Employees
- YSG N/A
- EDIT N/A
- Industry
- YSG Package Goods/Cosmetics
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YSG Consumer Discretionary
- EDIT Health Care
- Exchange
- YSG Nasdaq
- EDIT Nasdaq
- Market Cap
- YSG 396.8M
- EDIT 327.0M
- IPO Year
- YSG 2020
- EDIT 2016
- Fundamental
- Price
- YSG $3.89
- EDIT $3.21
- Analyst Decision
- YSG
- EDIT Buy
- Analyst Count
- YSG 0
- EDIT 13
- Target Price
- YSG N/A
- EDIT $9.38
- AVG Volume (30 Days)
- YSG 275.6K
- EDIT 2.1M
- Earning Date
- YSG 11-19-2024
- EDIT 11-04-2024
- Dividend Yield
- YSG N/A
- EDIT N/A
- EPS Growth
- YSG N/A
- EDIT N/A
- EPS
- YSG N/A
- EDIT N/A
- Revenue
- YSG $462,190,479.00
- EDIT $61,759,000.00
- Revenue This Year
- YSG $2.29
- EDIT N/A
- Revenue Next Year
- YSG $5.70
- EDIT N/A
- P/E Ratio
- YSG N/A
- EDIT N/A
- Revenue Growth
- YSG N/A
- EDIT 150.95
- 52 Week Low
- YSG $1.99
- EDIT $2.70
- 52 Week High
- YSG $4.89
- EDIT $11.69
- Technical
- Relative Strength Index (RSI)
- YSG 60.56
- EDIT 49.77
- Support Level
- YSG $3.77
- EDIT $2.70
- Resistance Level
- YSG $4.00
- EDIT $3.40
- Average True Range (ATR)
- YSG 0.16
- EDIT 0.25
- MACD
- YSG 0.02
- EDIT 0.02
- Stochastic Oscillator
- YSG 79.66
- EDIT 49.09
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The Group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.